Netherlands' Redcare Pharmacy slightly beats Q3 revenue estimates on strong prescription sales in Germany

Redcare Pharmacy NV

29/10/2026 05:41

Overview
Netherlands online pharmacy's Q3 revenue grew 18% yr/yr, slightly beating analyst expectations
Adjusted EBITDA margin rose 1.0pp to 3.4%, with adjusted EBITDA up 68% yr/yr
Growth driven by strong prescription sales in Germany and expanding customer base

Outlook
Redcare Pharmacy sees 2026 revenue growth of 16% to 18%
Company expects 2026 non-Rx revenue growth of 10% to 12%
Redcare Pharmacy forecasts 2026 Rx revenue in Germany at EUR 730 mln to EUR 760 mln

Result Drivers
GERMAN RX SALES - Company said strong prescription sales in Germany drove revenue growth
CUSTOMER BASE EXPANSION - Co attributed growth to increase in active customer base
LOWER MARKETING SPEND - Co said improved profitability was partly due to reduced marketing expenses and lower cost per order

Company press release: ID:nEQbPF3Vha

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Slight Beat*
EUR 847 mln
EUR 843.97 mln (3 Analysts)
Q3 Net Income
 
EUR 1 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy"
Wall Street's median 12-month price target for Redcare Pharmacy NV is €96.00, about 21.1% above its October 28 closing price of €79.25
The stock recently traded at 90 times the next 12-month earnings vs. a P/E of 274 three months ago

Reuters Recommended Reads
Oct 28 - Unilever tops Q3 sales estimates, raises dividend
Oct 27 - UK's Reckitt Q3 like-for-like revenue rises 3.2% on Emerging Markets growth
Oct 27 - Dutch regulator blocks takeover of Unilever's Unox brand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)